Cohance Lifesciences in Focus: ₹230 Mn Hyderabad Facility Plan
Cohance Lifesciences, formerly known as Suven Pharma, has been making waves in the pharmaceutical industry with its recent announcements. The company has planned to invest a massive ₹230 million (approximately $3.1 million) in setting up a new facility in Hyderabad, India. This move is expected to boost the company’s production capacity and further solidify its position in the market.
In addition to the Hyderabad facility, Cohance Lifesciences has also announced plans to invest $10 million in NJ Bio, US, for a cGMP bioconjugation suite to produce ADCs (Antibody-Drug Conjugates). ADCs are a type of targeted cancer therapy that has shown great promise in recent years. The bioconjugation suite will enable Cohance Lifesciences to produce high-quality ADCs for clinical trials and commercial use.
The Hyderabad facility, which is expected to be operational by the end of FY26, will be a 10,000 sq. ft. cGMP oligonucleotide facility. Oligonucleotides are short chains of nucleotides that play a crucial role in various biological processes. The facility will enable Cohance Lifesciences to produce a range of oligonucleotides, including siRNAs and miRNAs, for various therapeutic applications.
Cohance Lifesciences’ decision to invest in the Hyderabad facility is a strategic move to leverage the city’s reputation as a hub for pharmaceutical manufacturing. Hyderabad is home to some of the world’s leading pharma companies, and the city offers a conducive business environment, skilled workforce, and excellent infrastructure.
The company’s financial performance has been impressive in recent years. In FY25, Cohance Lifesciences reported a revenue growth of 9.1% YoY to ₹2,610.3 crore. The EBITDA margin was a healthy 31.3%, while the PAT (Profit After Tax) fell 4.8% to ₹546.3 crore. The company’s shares rose 4% to ₹985.75 on the back of these positive results.
Cohance Lifesciences’ plans to expand its production capacity and capabilities are expected to drive growth and increase its market share in the pharmaceutical industry. The company’s focus on research and development, as well as its commitment to quality and compliance, are key factors that have contributed to its success.
In a rapidly evolving pharmaceutical landscape, Cohance Lifesciences is well-positioned to take advantage of emerging trends and opportunities. The company’s investment in the Hyderabad facility and the cGMP bioconjugation suite in NJ Bio will enable it to stay ahead of the curve and maintain its position as a leader in the industry.
In conclusion, Cohance Lifesciences’ plan to invest ₹230 million in setting up a new facility in Hyderabad is a significant development in the pharmaceutical industry. The company’s commitment to expansion and growth is expected to drive revenue and profitability, and its focus on research and development will enable it to stay ahead of the competition.
